Marker Therapeutics, Inc. today announced updated clinical results from an ongoing investigator-sponsored Phase 1 trial led by the Baylor College of Medicine, evaluating the Company’s MultiTAA-specific T cell therapy in patients with advanced or metastatic pancreatic adenocarcinoma. Data from a cohort of patients receiving MultiTAA-specific T cell therapy in combination with standard-of-care chemotherapy in the first-line setting (Arm A), were reviewed today by lead investigator, Brandon G. Smaglo, M.D., FACP, as part of a poster session during the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting. ASCO is being held from Friday, May 29 through Sunday, May 31, 2020.
Marker Therapeutics, Inc. today announced that updated clinical data from an investigator-sponsored Phase 1/2 trial led by Baylor College of Medicine were selected for presentation during a poster session at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting.
Marker Therapeutics, Inc. today provided a corporate update and reported financial results for the first quarter ended March 31, 2020.
Marker Therapeutics today announced that it will host a conference call and webcast on Monday, May 11, 2020 at 5:00 p.m. Eastern Time to review its first quarter 2020 financial and operating results and provide a corporate update.
Marker Therapeutics today announced that the United States Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug designation to MT-401, a multi-tumor-associated antigen (MultiTAA)-specific T cell product for the treatment of patients with acute myeloid leukemia (AML), following allogeneic stem cell transplant.
Marker Therapeutics today provided a corporate update and reported financial results for the full year ended December 31, 2019.
Marker Therapeutics today announced that the Company has entered into a Common Stock Purchase Agreement of up to $30 million with Aspire Capital Fund, LLC, a Chicago-based institutional investor and long-term Marker shareholder.
Marker Therapeutics, Inc. (NASDAQ:MRKR) today announced that its President and Chief Executive Officer, Peter L. Hoang, will present at two upcoming investor conferences. Live webcasts of the presentations will be accessible from the investors section of the company’s website at markertherapeutics.com and will be available for replay following the event.
Marker Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Marker’s planned trial investigating safety and efficacy of its novel MultiTAA T cell therapy in patients with post-transplant acute myeloid leukemia (AML).
Houston, TX – November 25, 2019 – Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its President and Chief Executive Officer, Peter L. Hoang, will present at two upcoming investor conferences.